BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
A molecule linked to chronic inflammation disrupts the brain's ability to create new neurons, uncovering a pathway with ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel ...
Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...
Tumor necrosis factor (TNF) inhibitors protect patients with axial spondyloarthritis (axSpA) from hip and spine fractures better than other drugs. Large US insurance claims database study comparing ...
More than half of patients with treatment-resistant hidradenitis suppurativa achieved a 55% improvement in their disease after initiating golimumab, a tumor necrosis factor inhibitor, according to a ...
GMP Human TNF-alpha Protein (Cat. No. GMP-TNAH23) is expressed in human 293 cells (HEK293) and comprises amino acids Val 77 to Leu 233 (Accession # P01375). This protein has no "tag". It has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results